---
title: "Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held shareholder meetings"
description: "Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held its first extraordinary general meeting and class meetings for A and H shareholders on February 27, 2026. Shareholders approved the spin-off of Fosu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277211998.md"
published_at: "2026-02-27T14:08:48.000Z"
---

# Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held shareholder meetings

> Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held its first extraordinary general meeting and class meetings for A and H shareholders on February 27, 2026. Shareholders approved the spin-off of Fosun Adgenvax for an IPO on the Hong Kong Stock Exchange, including plans for independence and operational capability. The proposal for assured entitlements to H shareholders was approved at the H meeting but not at the A meeting. This news is generated by AI and should not be considered financial advice.

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held the 2026 first extraordinary general meeting, the 2026 first A shareholders’ class meeting and the 2026 first H shareholders’ class meeting on 27 February 2026. Shareholders approved proposals related to the spin-off of Fosun Adgenvax for an initial public offering of H shares and listing on the Main Board of the Hong Kong Stock Exchange, including the spin-off plan and proposal, the purpose and feasibility of the spin-off, maintenance of Shanghai Fosun Pharmaceutical’s independence and continuous operating capability, Fosun Adgenvax’s standardized operations capability, safeguarding shareholder and creditor interests, completeness and validity of procedures and documents, shareholdings of certain directors and senior management and affiliated parties in the company to be spun off, authorisation for the board to handle matters related to the spin-off, and the proposed assured entitlements to H shareholders in connection with the spin-off. At the A shareholders’ class meeting, the proposal on providing assured entitlements to H shareholders in connection with the spin-off was not approved. At the H shareholders’ class meeting, the same proposal was approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032860), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [600196.CN - FOSUN PHARMA](https://longbridge.com/en/quote/600196.CN.md)
- [02196.HK - FOSUN PHARMA](https://longbridge.com/en/quote/02196.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 復星醫藥在 2026 年特別會議上報告了強勁的股東出席率 | 上海復星醫藥（集團）有限公司在其 2026 年臨時股東大會上報告了強勁的股東出席率，超過 42% 的投票股本參與投票。由於利益衝突，部分董事在一項決議上選擇棄權，但沒有其他股東反對該決議，顯示出廣泛的支持。該股票（HK:2196）的最新分析 | [Link](https://longbridge.com/en/news/277222806.md) |
| 復星醫藥的子公司復星艾德計劃在香港證券交易所進行分拆上市 | 上海復星醫藥宣佈計劃在香港證券交易所進行其子公司復星阿德基瓦克斯的分拆上市。這一舉措是公司增強市場存在感和運營效率的戰略的一部分。該公告通過香港交易所的發行人信息服務發佈 | [Link](https://longbridge.com/en/news/273363479.md) |
| 這隻 AI 股票正在跑贏市場，並可能在 2026 年繼續上漲 | 這隻人工智能股票正在超越市場，並可能在 2026 年繼續上漲 | [Link](https://longbridge.com/en/news/276619136.md) |
| 首鋼世紀將股東大會推遲至 2026 年 6 月 | 首鋼世紀控股有限公司已將其股東大會推遲至 2026 年 6 月 30 日或之前，屆時將審議新的金融服務協議。相關通函原定於 2026 年 2 月 27 日發佈，現在將於 2026 年 5 月 31 日發出。此公告通過香港證券交易所的發行人信 | [Link](https://longbridge.com/en/news/277194266.md) |
| 頂級經濟學家 Steve Hanke 猛烈抨擊人工智能，認為其被過度炒作且具有危險性 | 頂尖經濟學家史蒂夫·漢克（Steve Hanke）批評人工智能，稱其被過度炒作且具有危險性。他對一篇討論人工智能的文章給予了 6.5/10 的評分，指出該文章有明確的論點和研究引用，但由於存在多個問題，尚不具備大規模傳播的準備 | [Link](https://longbridge.com/en/news/276542181.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.